Devin Quinlan
Principal at MPM BioImpact
Cambridge, Massachusetts
Overview
Work Experience
Principal
2023 - Current
Senior Associate
2020 - 2023
Associate
2018 - 2020
Intern
2016 - 2018
MPM BioImpact is a biotechnology investment firm specializing in managing early-stage venture and private/public impact.
Board Observer
2024
Board Observer
2023
Crossbow Therapeutics is a biotech company developing a new type of cancer treatment.
Raised $80,000,000.00 from Biotechnology Value Fund, Mirae Asset Venture Investment, Pfizer Venture Investments, Eli Lilly, Mirae Asset Capital, Polaris Partners and MPM Capital.
Member, Board of Directors
2023 - 2024
NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients.
Raised $122,500,000.00 from Leaps by Bayer, Invus, Arkin Holdings, Gordon Freeman, WTT Investment, Binney Street Capital, Sixty Degree Capital, Sanofi Ventures, MPM Capital and Catalio Capital Management.
PhD Student & Graduate Research Assistant
2012 - 2018
Teaching Assistant
2013 - 2013
Director of Investment Initiative; Graduate Director of Communications
2015 - 2016
MIT Biotech Group is a biotechnology research company that increases the pace of innovation by training student leaders.
Undergraduate Researcher
2010 - 2012
Education
Doctor of Philosophy (PhD)
2012 - 2018
B.S.
2008 - 2012